The company is aiming to create a suite of products that can help researchers and manufacturers engineer various genomes at scale for multiple purposes.
Researchers used Mission Bio's Tapestri assay to identify and monitor the evolution of cancer mutations in acute myeloid leukemia in response to targeted treatment.
The team evaluated various technologies in an attempt to develop a framework to compare future methods against and to serve as a guide for researchers.
New methods for spatial transcriptomic profiling include a sequential FISH-based method and one that makes use of DNA-barcoded bead arrays.
The method builds on a previous technique the group developed to measure transcriptomes and surface proteins from single cells.
Some of the mutational signatures the researchers observed were similar to ones previously seen in B cell tumors, underscoring the link between aging and cancer.
Both teams had sequencing data generated at BGI and said that going forward, it would be important to validate the technology outside of BGI.
LabCorp's Covance business plans to offer single-cell services on Mission Bio's platform to pharma and to explore its use in companion diagnostics.
The effort, outlined in a Development Cell paper published online today, aims to complement the ongoing Human Cell Atlas initiative, but with a focus on pediatric health.
The startup's technology, which it plans to launch through an early-access program this summer, is based on a cell fixing and combinatorial barcoding strategy.
A new analysis finds some cancers receive more nonprofit dollars than others.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.